These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37515226)

  • 1. Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody.
    Khalil AM; Piepenbrink MS; Markham I; Basu M; Martinez-Sobrido L; Kobie JJ
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
    Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.
    Piepenbrink M; Oladunni F; Nogales A; Khalil AM; Fitzgerald T; Basu M; Fucile C; Topham DJ; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    Microbiol Spectr; 2023 Aug; 11(4):e0472822. PubMed ID: 37318331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
    Madsen A; Dai YN; McMahon M; Schmitz AJ; Turner JS; Tan J; Lei T; Alsoussi WB; Strohmeier S; Amor M; Mohammed BM; Mudd PA; Simon V; Cox RJ; Fremont DH; Krammer F; Ellebedy AH
    Immunity; 2020 Oct; 53(4):852-863.e7. PubMed ID: 32976769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemagglutinin stalk-binding antibodies enhance effectiveness of neuraminidase inhibitors against influenza via Fc-dependent effector functions.
    Zhang A; Chaudhari H; Agung Y; D'Agostino MR; Ang JC; Tugg Y; Miller MS
    Cell Rep Med; 2022 Aug; 3(8):100718. PubMed ID: 35977467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza B virus neuraminidase: a potential target for next-generation vaccines?
    Do THT; Wheatley AK; Kent SJ; Koutsakos M
    Expert Rev Vaccines; 2024; 23(1):39-48. PubMed ID: 38037386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface.
    Wolters RM; Ferguson JA; Nuñez IA; Chen EE; Sornberger T; Myers L; Oeverdieck S; Raghavan SSR; Kona C; Handal LS; Esilu TE; Davidson E; Doranz BJ; Engdahl TB; Kose N; Williamson LE; Creech CB; Gibson-Corley KN; Ward AB; Crowe JE
    Immunity; 2024 Jun; 57(6):1413-1427.e9. PubMed ID: 38823390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
    Prachanronarong KL; Canale AS; Liu P; Somasundaran M; Hou S; Poh YP; Han T; Zhu Q; Renzette N; Zeldovich KB; Kowalik TF; Kurt-Yilmaz N; Jensen JD; Bolon DNA; Marasco WA; Finberg RW; Schiffer CA; Wang JP
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30381484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
    Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
    Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
    Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
    Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A computationally optimized broadly reactive hemagglutinin vaccine elicits neutralizing antibodies against influenza B viruses from both lineages.
    Carlock MA; Ross TM
    Sci Rep; 2023 Sep; 13(1):15911. PubMed ID: 37741893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
    Benjamin E; Wang W; McAuliffe JM; Palmer-Hill FJ; Kallewaard NL; Chen Z; Suzich JA; Blair WS; Jin H; Zhu Q
    J Virol; 2014 Jun; 88(12):6743-50. PubMed ID: 24696468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
    Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
    J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.
    DiLillo DJ; Palese P; Wilson PC; Ravetch JV
    J Clin Invest; 2016 Feb; 126(2):605-10. PubMed ID: 26731473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing antibodies recognizing different antigenic epitopes act synergistically against the influenza B virus.
    Zhai L; Zhang L; Jiang Y; Li B; Yang M; Victorovich KV; Aleksandrovna KT; Li M; Wang Y; Huang D; Zeng Z; Ren Z; Cao H; Zhu L; Wu Q; Xiao W; Zhang B; Wan C; Wang F; Xia N; Zhao W; Chen Y; Shen C
    J Med Virol; 2023 Jan; 95(1):e28106. PubMed ID: 36039848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.
    Mullarkey CE; Bailey MJ; Golubeva DA; Tan GS; Nachbagauer R; He W; Novakowski KE; Bowdish DM; Miller MS; Palese P
    mBio; 2016 Oct; 7(5):. PubMed ID: 27703076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.